J 2023

Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus

PULANIC, Drazen, Angelika BATOROVA, Imre BODO, Libor ČERVINEK, Ioana IONITA et. al.

Základní údaje

Originální název

Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus

Autoři

PULANIC, Drazen (garant), Angelika BATOROVA, Imre BODO, Libor ČERVINEK (203 Česká republika, domácí), Ioana IONITA, Toshko LISSITCHKOV, Anahit MELIKYAN a Maria PODOLAK-DAWIDZIAK

Vydání

Annals of hematology, New York, Springer Verlag, 2023, 0939-5555

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 3.500 v roce 2022

Kód RIV

RIV/00216224:14110/23:00130690

Organizační jednotka

Lékařská fakulta

DOI

UT WoS

000939356900001

Klíčová slova anglicky

Immune thrombocytopenia; Thrombopoietin receptor agonists; Systematic review; Consensus; Eltrombopag; Romiplostim; Avatrombopag

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 2. 5. 2023 09:35, Mgr. Tereza Miškechová

Anotace

V originále

There are currently three thrombopoietin receptor agonists (TPO-RAs) approved in Europe for treating patients with immune thrombocytopenia (ITP): romiplostim (Nplate (R)), eltrombopag (Revolade (R)), and avatrombopag (Doptelet (R)). However, comparative clinical data between these TPO-RAs are limited. Therefore, the purpose of this study was to perform a literature review and seek expert opinion on the relevance and strength of the evidence concerning the use of TPO-RAs in adults with ITP. A systematic search was conducted in PubMed and Embase within the last 10 years and until June 20, 2022. A total of 478 unique articles were retrieved and reviewed for relevance. The expert consensus panel comprised ITP senior hematologists from eight countries across Central Europe. The modified Delphi method, consisting of two survey rounds, a teleconference and email correspondence, was used to reach consensus. Forty articles met the relevancy criteria and are included as supporting evidence, including five meta-analyses analyzing all three European-licensed TPO-RAs and comprising a total of 31 unique randomized controlled trials (RCTs). Consensus was reached on seven statements for the second-line use of TPO-RAs in the management of adult ITP patients. In addition, the expert panel discussed TPO-RA treatment in chronic ITP patients with mild/moderate COVID-19 and ITP patients in the first-line setting but failed to reach consensus. This work will facilitate informed decision-making for healthcare providers treating adult ITP patients with TPO-RAs. However, further studies are needed on the use of TPO-RAs in the first-line setting and specific patient populations.